scholarly journals De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

2019 ◽  
Vol 6 (7) ◽  
pp. e375-e383 ◽  
Author(s):  
Richard E Clark ◽  
Fotios Polydoros ◽  
Jane F Apperley ◽  
Dragana Milojkovic ◽  
Katherine Rothwell ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Treatment Discontinuation ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Complete Treatment

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

2016 ◽  
Vol 91 (11) ◽  
pp. E480-E481 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Simona Deplano ◽  
Jamshid Khorashad ◽  
Letizia Foroni ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Cognitive Dysfunction ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy

scholarly journals GRP-011 Adherence to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

2013 ◽  
Vol 20 (Suppl 1) ◽  
pp. A4.3-A5
Author(s):  
V González Rosa ◽  
MM Viña Romero ◽  
F Gutiérrez Nicolás ◽  
R Gavira Moreno ◽  
MT Moreno Carvajal ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document